Document is current
Any future updates will be listed below
-
Authors
Burmeister, Thomas https://orcid.org/0000-0003-4843-2876
Ströh, Aeint-Steffen https://orcid.org/0000-0002-7463-5354
Kehden, Britta
Trautmann, Heiko https://orcid.org/0000-0002-9000-4747
Meyer, Claus
Marschalek, Rolf https://orcid.org/0000-0003-4870-3445
Larghero, Patrizia
Schwartz, Stefan https://orcid.org/0000-0001-8833-5793
Steffen, Björn https://orcid.org/0009-0002-6693-4079
Spriewald, Bernd
Heinicke, Thomas https://orcid.org/0000-0002-4049-7854
Jäkel, Nadja https://orcid.org/0000-0001-6162-515X
Westermann, Jörg
Nachtkamp, Kathrin
Viardot, Andreas
Topp, Max S.
Neumann, Martin
Baldus, Claudia D. https://orcid.org/0000-0002-0748-834X
Gökbuget, Nicola
Brüggemann, Monika
- License Information
-
More Information
Article History
Received: 30 July 2023
Revised: 28 February 2024
Accepted: 28 February 2024
First Online: 22 March 2024
Competing interests
: MB is contracted to carry out research for Affimed, Amgen, Regeneron, the advisory board of Amgen, Incyte, Speaker bureau of Amgen, Janssen, Pfizer, Roche. SS is advisory board member of AMGEN and received honoraria as a speaker bureau member of AMGEN. CB is contracted to carry out research for Novartis, the advisory board of Amgen. TB received speakers’ honoraria from Novartis and Pfizer. The other authors declare that they have no conflict of interest.
